SUZHOU/BEIJING (Reuters) - Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.
China’s success in driving down COVID-19 infections has made it harder to conduct large-scale vaccine trials, and so far only a few countries have agreed to work with it.
“We are contacting Russia, Brazil, Chile and Saudi Arabia (for the Phase III trial), and it’s still in discussion,” Qiu Dongxu, executive director and co-founder of CanSino, told an anti-viral drug development conference in Suzhou, in eastern China.
He said its Phase III trial was likely to start “pretty soon,” and the company plans to recruit 40,000 participants for the test.
Its COVID-19 candidate, Ad5-nCov, became the first in China to move into human testing in March but is running behind other potential vaccines in terms of trial progress. Two experimental vaccines developed by Sinovac Biotech and a unit of China National Pharmaceutical Group (Sinopharm) are already approved for Phase III trials.
Qiu said its Phase II trial involving 508 people has yielded “much better” results than the Phase I about the safety and ability to trigger immune response. He did not disclose specific evidence.
He said its new factory under construction in China will allow it to produce 100-200 million doses of coronavirus vaccines per year by early 2021.
China’s military, whose research unit is co-developing the vaccine candidate, approved its military use last month, while Sinopharm’s two experimental shots are offered to employees at state-owned firms travelling overseas.
Zeng Guang, former chief epidemiologist at the Chinese Center for Disease Control and Prevention, told the conference that Chinese construction groups overseas in particular are keen to take experimental vaccines.
He also said discussion should start whether to launch emergency inoculation of experimental vaccines “right now.”
There are no approved vaccines yet for COVID-19, a respiratory disease caused by the new coronavirus, which has killed more than half a million people globally.
(This story corrects 4th and 6th paragraphs to remove references to multiple Phase III and Phase II trials)
Reporting by Roxanne Liu in Suzhou and Tony Munroe in Beijing; Editing by Miyoung Kim and Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.